Last reviewed · How we verify
CD70 CAR T-cells
CD70 CAR T-cells is a Biologic drug developed by Zhejiang University. It is currently in Phase 1 development. Also known as: CD70 CAR-T cells injection.
CD70 CAR T-cells are being studied in clinical trials for the treatment of relapsed or refractory plasma cell neoplasms, as well as other conditions such as systemic lupus erythematosus and acute myeloid leukemia. The mechanism of CD70 CAR T-cells is classified as somatic cell supplemental therapy, which involves the use of autologous cells that have been genetically modified to target specific cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CD70 CAR T-cells |
|---|---|
| Also known as | CD70 CAR-T cells injection |
| Sponsor | Zhejiang University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (PHASE1, PHASE2)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (PHASE1)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (PHASE1)
- CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (PHASE1)
- CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms (EARLY_PHASE1)
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (PHASE1)
- Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD70 CAR T-cells CI brief — competitive landscape report
- CD70 CAR T-cells updates RSS · CI watch RSS
- Zhejiang University portfolio CI
Frequently asked questions about CD70 CAR T-cells
What is CD70 CAR T-cells?
Who makes CD70 CAR T-cells?
Is CD70 CAR T-cells also known as anything else?
What development phase is CD70 CAR T-cells in?
Related
- Manufacturer: Zhejiang University — full pipeline
- Also known as: CD70 CAR-T cells injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing